D
Y-mAbs Therapeutics, Inc. YMAB
$4.04 $0.164.12% NASDAQ
Recommendation
Prev Close
$3.88
Volume
2,312
Avg Vol (90D)
383,285
Market Cap
$175.45M
Dividend & Yield
--
52-Week Range
$3.83 - $16.11
P/E (TTM)
--
EPS (TTM)
-$0.6704
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
5/7/2025 - Zacks Investment Research
Y-mAbs Therapeutics (YMAB) Gains NCCN Recommendation for Naxitamab Treatment YMAB Stock News
5/7/2025 - GuruFocus
Y-mAbs Therapeutics announces naxitamab-gqgk recommended by NCCN
5/7/2025 - The Fly
Y-mAbs Announces Update to National Comprehensive Cancer Network (NCCN ) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA )
5/7/2025 - Globe Newswire
Y-mAbs Therapeutics (YMAB, $3.86) Moving Average Convergence Divergence (MACD) Histogram turned negative on May 6, 2025
5/7/2025 - Tickeron - Stocks
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
5/6/2025 - Globe Newswire
Y-mAbs Therapeutics (YMAB, $4.41) Moving Average Convergence Divergence (MACD) Histogram turned positive on May 2, 2025
5/3/2025 - Tickeron - Stocks
Caligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
5/3/2025 - MarketBeat
Y-mAbs Therapeutics (YMAB) Projected to Post Earnings on Tuesday
5/1/2025 - MarketBeat
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
4/30/2025 - Zacks Investment Research
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
4/29/2025 - Zacks Investment Research
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price
4/29/2025 - Simply Wall St
Boothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
4/29/2025 - MarketBeat
Y-Mabs Therapeutics (YMAB) Receives a Buy from JonesTrading
4/28/2025 - TipRanks Financial Blog
Y-mAbs Therapeutics (YMAB) Showcases CD38-SADA Data at AACR 2025 YMAB Stock News
4/27/2025 - GuruFocus
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
4/27/2025 - TipRanks Financial Blog
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
4/27/2025 - The Fly
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
4/27/2025 - Globe Newswire
Boothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
4/27/2025 - Ticker Report
Brookline Capital Management Weighs in on YMAB Q1 Earnings
4/27/2025 - MarketBeat
Y-mAbs Therapeutics (YMAB) Begins Phase 1 Trial for Non-Hodgkin Lymphoma Treatment YMAB Stock News
4/25/2025 - GuruFocus
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
4/25/2025 - Globe Newswire
Y-mAbs Therapeutics (YMAB, $4.13) entered Downtrend as Momentum indicator drops below 0 level on Apr 24, 2025
4/25/2025 - Tickeron - Stocks
Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of America
4/24/2025 - MarketBeat
Y-mAbs Therapeutics (YMAB, $4.12) entered Uptrend as Momentum indicator ascends above 0 level on Apr 23, 2025
4/24/2025 - Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
$87.69M
EBITDA (TTM)
-$28.38M
EBIT (TTM)
-$28.91M
Net Income (TTM)
-$29.67M
Balance Sheet
Total Assets (Q)
$119.90M
Total Debt (Q)
$820.00K
Total Liabilities (Q)
$27.90M
Book Value Per Share (Q)
$2.05
Cash Flow
Cash from Operations (TTM)
-$15.71M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$4.31M
Net Change in Cash (TTM)
-$11.40M
Filings
Filing Date
Tuesday, March 4, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.46
7-Day Total Return
-3.81%
30-Day Total Return
-16.53%
60-Day Total Return
-29.98%
90-Day Total Return
-49.50%
Year to Date Total Return
-49.31%
1-Year Total Return
-70.32%
2-Year Total Return
-40.32%
3-Year Total Return
-50.85%
5-Year Total Return
-89.86%
52-week Low
May 07, 2025 - $3.83
52-week High
Nov 07, 2024 - $16.11
Valuation
Market Cap
$175.45M - Micro Cap
Enterprise Value
$109.03M
Price/Sales (TTM)
1.99
Price/Book (Q)
1.90
Dividends and Shares
Shares Outstanding
44.88M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ymabs.com
Phone Number
(646)-885-8505
Address
202 Carnegie Center
Princeton, NJ 08540
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the... more
NASDAQ 05/08/2025 4:00PM Eastern Quotes delayed